For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a ...

On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis ...

In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

The rise in use of GLP-1 medications is driving a convergence between pharmaceutical therapies and consumer health and ...

Creating and bringing new medicines to patients is a uniquely complicated process. It requires robust scientific research, business acumen, tremendous financial investment, and patience — even when ...

Research Use Only (RUO) lipid nanoparticle (LNP) reagents to deliver RNA into hematopoietic stem cells (HSCs) for cell and gene therapy applications. The CD34+ HSC LNP kit is an LNP reagent mix ...

GenVoy-ILM™ T cell Kit for mRNA is a lipid nanoparticle (LNP) reagent mix optimized for the delivery of mRNA or CRISPR Cas9 mRNA with gRNA into human primary T cells using LNPs prepared on the ...

On a recent episode of the Business of Biotech podcast, Brian Lortie, president and CEO of Uniquity Bio, offered up useful advice about the complex process of building and leading a biotech startup in ...